SignalXSignalX

CL Colgate-Palmolive

FY2025 10-K
Filed: Feb 23, 2026
Health Care
Perfumes, Cosmetics & Other Toilet PreparationsSEC EDGAR
Colgate-Palmolive Overview

Colgate-Palmolive (CL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Two-segment model: Oral/Personal/Home Care (77% combined net sales) and Pet Nutrition (23%), sold in 200+ countries
  • • New C-suite hires: Shane Grant (COO Americas, ex-Danone) and John Hazlin (Chief Growth Officer) added in 2025
+3 more insights

Management Discussion & Analysis

  • • Revenue $20,382 in 2025, up 1.4% YoY; organic sales +1.4% driven by 2.1% net pricing, offset by -0.4% volume and -0.3% FX
  • • GAAP operating margin 16.2% vs 21.2% (−500 bps) due to $919 pretax Filorga impairment; non-GAAP operating margin 21.3% vs 21.7% (−40 bps); gross margin 60.1% vs 60.5%
+3 more insights

Risk Factors

  • • FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products — reformulation or restriction could materially impact core product lines
  • • Eurasia operations ~1% of consolidated net sales and ~2% of consolidated operating profit; cash repatriation from Russia blocked and financial institution access constrained
+3 more insights

Financial Summary
XBRL

Revenue

$20.4B

Net Income

$2.1B

Gross Margin

60.1%

Operating Margin

16.2%

Net Margin

10.5%

ROE

3948.1%

Total Assets

$16.3B

EPS (Diluted)

$2.63

Operating Cash Flow

$4.2B

Source: XBRL data from Colgate-Palmolive FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Colgate-Palmolive

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available